Silene Biotech
Facts
- Sectors
- Biotech, Life Sciences, Stem Cell, Cryopreservation, Biobanking
- Stage
- Acquired
Recent coverage
Front-page news, podcasts and videos about Silene Biotech
Curi Bio raises $10M to advance iPSC-based 3D tissue drug-discovery platforms including Mantarray
Seattle-based Curi Bio raised $10 million in Series A financing to advance its human iPSC-based drug discovery platforms, including 3D engineered tissue products like Mantarray and Cytostretcher. The company provides customized assay and screening services for cardiac, musculoskeletal and neuromuscular models and has prior funding including $6M this spring and over $6M in NIH grants.
Curi Bio raises $6M Series A led by Dynamk Capital to advance human stem cell drug-discovery platforms
Seattle stem-cell startup Curi Bio raised $6 million in a Series A led by Dynamk Capital to advance its human stem cell platforms for drug discovery, bringing total funding to $16.8 million.
Ralph de la Vega, ex‑AT&T vice chairman, joins Outreach board as startup hits $1.33B valuation; Flyhomes names two VPs
Former AT&T vice chairman Ralph de la Vega joined Seattle sales engagement startup Outreach's board after meeting CEO Manny Medina; Outreach is a $1.33B-valued unicorn that raised $50M in June and employs about 700. Seattle real-estate startup Flyhomes also appointed two VPs: Adam Hopson (growth and strategy) and Rehan Mohammad (finance and business operations).
